Isolated presence of antibody to hepatitis B core antigen in injection drug users: do they need to be vaccinated?

Gianluca Quaglio, Fabio Lugoboni, Sandro Vento, Alessandro Lechi, Augusto Accordini, Carlo Bossi, Marco Faccini, Valerio Mecenero, Alessandro Pani, Maurizio Pantalena, Margherita Residori, Paolo Mezzelani

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

In a study of 497 injection drug users who had isolated presence of antibody to hepatitis B core antigen (anti-HBc) at the time of enrollment, 404 (81%) retained this condition after a mean of 49 months of follow-up, during which time no new hepatitis B surface antigen marker was detected. These findings support the hypothesis that patients with isolated presence of anti-HBc have strong resistance to reinfection and do not need vaccination.

Original languageEnglish
Pages (from-to)E143-144
JournalClinical infectious diseases: an official publication of the Infectious Diseases Society of America
Volume32
Issue number10
DOIs
Publication statusPublished - Oct 1 2001

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Isolated presence of antibody to hepatitis B core antigen in injection drug users: do they need to be vaccinated?'. Together they form a unique fingerprint.

  • Cite this

    Quaglio, G., Lugoboni, F., Vento, S., Lechi, A., Accordini, A., Bossi, C., Faccini, M., Mecenero, V., Pani, A., Pantalena, M., Residori, M., & Mezzelani, P. (2001). Isolated presence of antibody to hepatitis B core antigen in injection drug users: do they need to be vaccinated? Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 32(10), E143-144. https://doi.org/10.1086/320162